Skip to content

The Effect of Propolis in Tinea Pedis Treatment: A Randomized Controlled Study

The Effect of Propolis in Tinea Pedis Treatment: A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04789083
Enrollment
96
Registered
2021-03-09
Start date
2022-02-03
Completion date
2022-08-30
Last updated
2023-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Foot Care, Nurse's Role, Patient Education

Keywords

nursing, nurse coaching, patient education, complementary therapy, althernative therapy

Brief summary

Tineapedis is an important health problem. Providing foot care in tinea pedis treatment contributes positively to the treatment. In addition, alternative treatments can also be used. In this study, the randomization study group will be divided into three. Medical treatment and foot care training will be applied to the first group, medical treatment and propolis to the second group, medical treatment and plassebo to the control group. Foot care training will be given by nurse coaching. Times of all three groups and their response to treatment will be evaluated.

Detailed description

1. Study Identification: Randomised Controlled Trial 2. Study Status: This will begin 3. Sponsor/Collaborators: SBS Scientific Bio Solutions Inc. 4. Oversight: Patients will be given foot care training. At the same time, a phone call will be provided by the research nurse every week. Evaluation will be made at the end of 2 months 5. Study Description It was planned as a double-blind randomized controlled study. The person conducting the randomizer, the person making the statistics and the person performing the medical examiner will be blinded. Power analysis was made using the G \* Power (3.1.9.4) program, 0.05 margin of error and 85% power were accepted. A total of 96 people were divided into three groups. Groups were composed of 36 people, including 10% losses for each group. Inclusion Criteria: Not being pregnant Not being breastfeeding Not having confusion Not being immunosuppressed Not using systemic cortisone Not having any dermatological problems (psoriasis, contact dermatitis, etc.) that will affect the treatment. Agree to participate in research Being accessible by phone Having no problems communicating by phone Not having problems with physical care Exclusion Criteria: Pregnant / nursing women Using systemic antifungal therapy Using systemic croticosteroids In the process of treatment for oncological reasons Are using immunosuppressants Dermatological disease (contact dermatitis, psoriasis) Under the age of 18 and over the age of 64 Have cognitive problems There is no telephone / telephone number within reach Individuals who have difficulties in speaking and understanding Turkish will be excluded from the study. Medical treatment applied to all three groups: Sertaconazole nitrate (2%), 1x1, externally Terbinafine hydrochloride (250 mg), 1x1, oral Propolis treatment: Alcoholic extract of propolis will be used topically 2x1. Plassebe: Sterile distilled water 2x1 will be used. Plassebo and propolis extrat will be prepared in the same packages. Nurse coaching will continue by the nurse, who received coaching training, using the training booklet, with the first meeting face-to-face and subsequent calls over the phone. Interviews will be held once every two weeks.Each participant will be followed for two months. Their treatment and nurse coaching will also continue for two months. The nurse coach will coach each patient at least four times. Each coaching session will last at least 30 minutes. In the evaluation; Dermatological Quality of Life Scale will be used with the global evaluation of the patient and the doctor. Approval was obtained from Medipol University Traditional and Alternative Medicine Practices Ethics Committee for the research. 6. Conditions and Keywords Propolis, foot care, nursing education 7. Study Design: Randomised Controlled Trial 8. Arms, Groups, and Interventions There are 2 experiments and 1 control group in the study. Routine antifungal therapy will be applied to all groups. Apart from this, one group will be given propolis, another group will be given plassebo. Another group will be given foot care training. 9. Outcome Measures Doctor's global assessment Patient's global assesment Dermatological quality of life scale 10. Eligibility The study was planned in accordance with the Turkish Ministry of Health rules. 11. Contacts, Locations, and Investigator Information Rukiye Burucu Necmettin Erbakan Üniversitesi Seydişehir SBF Seydişehir/ Konya rburucu@hotmail.com 05062347525 12. IPD Sharing Statement...

Interventions

OTHERPropholis extrate

Plassebo

Sponsors

Necmettin Erbakan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This study is a double blind randomized controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Not being pregnant * Not being breastfeeding * Not having confusion * Not being immunosuppressed * Not using systemic cortisone * Not having any dermatological problems (psoriasis, contact dermatitis, etc.) that will affect the treatment. * Agree to participate in research * Being accessible by phone * Having no problems communicating by phone * Not having problems with physical care

Exclusion criteria

* Pregnant / nursing women * Using systemic antifungal therapy * Using systemic croticosteroids * In the process of treatment for oncological reasons * Are using immunosuppressants * Dermatological disease (contact dermatitis, psoriasis) * Under the age of 18 and over the age of 64 * Have cognitive problems * There is no telephone / telephone number within reach * Individuals who have difficulties in speaking and understanding Turkish will be excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation3 monthDermatological Quality of Life Scale

Secondary

MeasureTime frameDescription
Doctor's an patient's global3 monthDoctor's global assessment

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026